Introduction {#s1}
============

Cancer is a complicated disease resulting from the combined effect of genetic susceptibility and external elements such as lifestyle and inflammation [@pone.0073213-Yaghoobi1], [@pone.0073213-Berlau1]. The role of inflammation in carcinogenesis is a pivotal issue. Studies have demonstrated that inflammation-associated molecules are associated with a majority of cancer types, and these molecules are activated by various elements related to environment and lifestyle [@pone.0073213-Sethi1]. Signs of inflammation, including cytokines, chemokines, and immune cells, have been identified in many precancerous and cancerous tissues [@pone.0073213-Mantovani1]. Several models have typically demonstrated that inflammation induces certain cancers: chronic intestinal inflammation has been associated with colon cancer; *Helicobacter pylori* (HP) with gastric cancer; human papilloma virus (HPV) infection with cervical carcinoma; and hepatitis B virus (HBV) infection with hepatocellular carcinoma [@pone.0073213-Rubin1]--[@pone.0073213-Hardbower1]. Chronic inflammation of the colon (e.g., ulcerative colitis) markedly increases the risk of developing colon cancer [@pone.0073213-Ekbom1]. The persistent presence of pathogenic microorganisms causes chronic inflammation that raises the likelihood of some cancers [@pone.0073213-Hussain1].

Cyclooxygenase-2 (COX-2), known as prostaglandin-endoperoxide synthase 2 (PTGS2), is a rate-limiting enzyme produced during the production of prostaglandins, and prostaglandins play an important role in inflammation, tumor progression, and metastasis [@pone.0073213-Wang1]. COX-2 is often undetectable in normal tissue, whereas in tumor tissue specimens its expression is observably higher [@pone.0073213-Cao1]. It has been reported that COX-2 overexpression contributes to carcinogenesis by increasing cell proliferation, suppressing apoptosis, enhancing invasiveness, and inducing chronic activation of immune responses [@pone.0073213-OByrne1], [@pone.0073213-Tsujii1].

Genetic variants may affect the expression of COX-2, and the underlying mechanism is considered to occur through self-regulated transcriptional activity resulting from variations in the capability of its promoter region to bind with certain nuclear proteins [@pone.0073213-Szczeklik1]. The single-nucleotide polymorphism (SNP) COX-2-765G\>C (rs20417) is a functional, extensively studied polymorphism that features guanine (G) converting to cytosine (C) at position-765 bp of the promoter region, altering the transcription activity of the COX-2 gene. Several studies have demonstrated the COX-2-765 G\>C polymorphism to be associated with increased risk of human cancers such as gastric cancer, colorectal cancer, prostate cancer, breast cancer, and others [@pone.0073213-Zhang1]--[@pone.0073213-Balistreri1]. However, in other studies, the COX-2-765 C allele was not observed to be associated with cancer risk [@pone.0073213-Cox1]. To further ascertain the relationship between COX-2-765 G\>C and cancer risk, several further meta-analyses were performed, but regrettably, the results among studies have varied for different cancer types [@pone.0073213-Liu1]--[@pone.0073213-Dong1]. Recently, additional studies of the COX-2-765 G\>C polymorphism in several cancer types have been reported; therefore, we conducted this meta-analysis to synthesize the results of these studies and to establish a more durable conclusion.

Methods {#s2}
=======

Publication Search {#s2a}
------------------

A systematic literature search through February 12, 2013, was performed using the databases of PubMed and EMBASE and searching for the following terms: (cyclooxygenase-2 or COX-2 or PTGS2) and (polymorphism or polymorphisms or variant or variants or genotype) and (cancer or carcinoma or neoplasm). To expand our investigation, we also searched China National Knowledge Infrastructure (CNKI) database using the following terms in Chinese: COX-2, cancer risk, and polymorphism. References for these articles and eligible literature from review articles were also collected.

Inclusion and Exclusion Criteria and Data Extraction {#s2b}
----------------------------------------------------

Article selection for the meta-analysis used the following inclusion criteria: 1) information on the evaluation of COX-2-765G\>C (rs20417) polymorphism and cancer risk; 2) case-controlled study; 3) human subjects; and 4) sufficient genotype data to calculate the odds ratios (ORs) with 95% confidence intervals (CIs). When the same or overlapping populations were included in several publications, the studies with larger sample size were selected. When pertinent data were not included or data presented were unclear, we contacted the authors to collect more data or to clarify the study results. Exclusion criteria were the following: 1) no controls; 2) overlapping study populations; 3) not enough pertinent data; and 4) departure from the Hardy-Weinberg equilibrium (HWE) method in control subjects.

The following data were extracted from all eligible publications: the first author, publication year, cancer type, country and race of the study population, control source (population-based (PB), hospital-based (HB) and family-based (FB)), total number of cases and controls studied, number of cases and controls with the wild-type, heterozygous, and homozygous genotypes, and with the minor allele frequency (MAF). Ethnic subgroups were categorized as Caucasian, Asian, American, and African. For case-control studies with subjects of different races, data were extracted separately for each ethnic group whenever possible. When a study did not include detailed genotypes of each ethnic group, or if it was difficult to discriminate the ethnicity of participants according to the data presented, the study was termed "mixed". If the study was performed in different counties or regions and the subgroups were indistinguishable in the report, the study was termed "multicenter". All data were independently extracted by two investigators according to these selection criteria. Disagreement was resolved by discussion.

Statistical Methods {#s2c}
-------------------

We utilized odds ratios (ORs) with 95% (confidence intervals) CIs to assess the strength of association between the COX-2-765G\>C polymorphism and cancer risk. The pooled ORs with 95% CIs were calculated in a co-dominant model (variant homozygote *vs.* heterozygote) and a dominant model (variant homozygote+heterozygote *vs.* wild-type homozygote). Subgroup analyses were stratified by ethnicity and cancer type.

We used the goodness-of-fit χ^2^ test to evaluate HWE for control subjects in each study, and we considered P\<0.05 to representative significant departure from HWE [@pone.0073213-Song1]. The heterogeneity assumption was verified using the χ^2^-based Q-test. Q-test results of P\>0.05 suggested a lack of heterogeneity among studies, so the pooled OR of all studies was calculated using the fixed-effect model based on the Mantel--Haenszel method. Otherwise, we used the random-effect model, based on the DerSimonian--Laird method, which provides a larger pool of 95% CIs from studies differing among themselves [@pone.0073213-Ma1], [@pone.0073213-Chen1].

We also conducted a sensitivity analysis by excluding each study, one at a time, and recalculating the ORs and 95% CIs to assess the effects of each study on the pooled risk of cancer [@pone.0073213-Ke1]. Then we performed an estimate of potential publication bias using the funnel plot, in which the standard error of log (OR) of every study was plotted against its log (OR) [@pone.0073213-Wei1], and an asymmetric plot indicated a potential publication bias. We assessed funnel-plot asymmetry using Egger's linear regression test, a linear regression method of evaluating funnel plot asymmetry on the natural logarithm scale of the OR [@pone.0073213-Liu2]. The significance of the intercept was determined using the t-test suggested by Egger, and p\<0.05 was considered representative of statistically significant publication bias [@pone.0073213-Egger1], [@pone.0073213-Liu3]. In cases of publication bias, the Duval and Tweedie nonparametric ''trim and fill.'' method was performed to adjust for it [@pone.0073213-Duval1]. All of the statistical tests were performed using STATA version 10.0 (Stata Corporation, College Station, TX).

Results {#s3}
=======

Eligible Studies Characteristics {#s3a}
--------------------------------

A total of 579 publications from the MEDLINE, EMBASE, and CNKI databases were reviewed using the specified key words. After a review of titles and abstracts, 494 publications were excluded according to our criteria. From the remaining 85 studies on COX-2-765G\>C polymorphism and susceptibility to cancer that met our inclusion criteria, we eliminated 5 publications due to insufficient genotype data, 11 due to deviation from Hardy-Weinberg equilibrium in controls, and 4 due to overlap with other studies. Finally, 65 articles, including with 29,487 cancer cases and 39,212 non-cancer controls, were included in this meta-analysis. A flow chart of the study selection procedure is shown in [**Fig. 1**](#pone-0073213-g001){ref-type="fig"}.

![Flow chart of studies selected procedure of this meta-analysis.](pone.0073213.g001){#pone-0073213-g001}

The main characteristics of the studies are listed in [**Table 1**](#pone-0073213-t001){ref-type="table"}. The respective studies focused on the following cancer types: 13 studies investigated colorectal carcinoma [@pone.0073213-Andersen1], [@pone.0073213-Tan1]--[@pone.0073213-Thompson1], 9 gastric cancer [@pone.0073213-Zhang1], [@pone.0073213-Li1]--[@pone.0073213-Bi1], 8 prostate cancer [@pone.0073213-Balistreri1], [@pone.0073213-Cheng1]--[@pone.0073213-Panguluri1], 6 esophageal cancer [@pone.0073213-Kristinsson1]--[@pone.0073213-Bye1], 3 colorectal adenoma [@pone.0073213-Ulrich1]--[@pone.0073213-Gunter1], 4 cancer of head and neck (HNC) [@pone.0073213-Peters1]--[@pone.0073213-Chiang1], 4 breast cancer [@pone.0073213-Cox1], [@pone.0073213-Gao1]--[@pone.0073213-Dossus1], 3 lung cancer [@pone.0073213-Coskunpinar1]--[@pone.0073213-Liu5], 3 lymphoma [@pone.0073213-Hoeft1]--[@pone.0073213-Chang1], 3 skin cancer [@pone.0073213-Lira1]--[@pone.0073213-Vogel1], 2 leukemia [@pone.0073213-Wang3], [@pone.0073213-Zheng1], 2 pancreatic cancer [@pone.0073213-Zhao1], [@pone.0073213-Xu1], 2 ovarian cancer [@pone.0073213-Agachan1], [@pone.0073213-Pinheiro1], 2 hepatocellular carcinoma (HCC) [@pone.0073213-Chang2], [@pone.0073213-He1], 1 cervical cancer [@pone.0073213-Pandey1], 1 glioblastoma [@pone.0073213-Schwartzbaum1], and 1 combination of colorectal and esophageal cancers, which were indistinguishable [@pone.0073213-Biramijamal1]. Twenty-five studies used Asian research subjects, 25 Caucasian, 9 American, 3 African, and 5 used mixed ethnic subjects. Thirty-five study designs were population based (PB), 31 were hospital based (HB), and 1 was family based (FB). The genotyping method used in most of the studies (56/67) was polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP).

10.1371/journal.pone.0073213.t001

###### Main characteristics of studies involved in this meta-analysis for an association between COX-2-765 G\>C polymorphism and cancer risk.

![](pone.0073213.t001){#pone-0073213-t001-1}

  First author    Year               Cancer type                 Country        Race      Study design             Genotype method              Case   Control   MAF[3](#nt103){ref-type="table-fn"} of controls   HWE[4](#nt104){ref-type="table-fn"}(P)
  -------------- ------ ------------------------------------- -------------- ----------- -------------- -------------------------------------- ------ --------- ------------------------------------------------- ----------------------------------------
  Gao             2007                 Breast                     China         Asian          PB                      PCR-RFLP                 601      643                          0.05                                          0.70
  Cox             2007                 Breast                    America        mixed          PB                      PCR-RFLP                 1243    1715                          0.17                                          0.58
  Piranda         2010                 Breast                   Brazilian     American         HB                      PCR-RFLP                 308      264                          0.29                                          0.21
  Dossus          2010                 Breast                  Multicenter      mixed          PB                      PCR-RFLP                 6254    8092                          0.84                                          0.13
  Tan             2007          Colorectal carcinoma              China         Asian          PB                      PCR-RFLP                 1000    1300                          0.02                                          0.37
  Hamajima        2001          Colorectal carcinoma              Japan         Asian          HB                      PCR-CTPP                 148      241                          0.02                                          0.70
  Xing            2008          Colorectal carcinoma              China         Asian          HB                      PCR-RFLP                 137      199                          0.08                                          0.84
  Koh             2004          Colorectal carcinoma            Singapore       Asian          PB                      PCR-RFLP                 310     1177                          0.05                                          0.43
  Iglesias        2009          Colorectal carcinoma              Spain       Caucasian        HB                      PCR-RFLP                 284      123                          0.21                                          0.48
  Gong            2009          Colorectal carcinoma             America      American         PB                      PCR-RFLP                 162      211                          0.23                                          0.67
  Wang            2012          Colorectal carcinoma           Multicenter      mixed          FB                      PCR-RFLP                 305      359                          0.18                                          0.49
  Daraei          2012          Colorectal carcinoma               Iran       Caucasian        PB                      PCR-RFLP                 110      120                          0.32                                          0.20
  Cox             2004          Colorectal carcinoma              Spain       Caucasian        HB                      PCR-RFLP                 220      257                          0.19                                          0.73
  Hoff            2009          Colorectal carcinoma           Netherlands    Caucasian        HB                      PCR-RFLP                 326      369                          0.17                                          0.26
  Andersen        2009          Colorectal carcinoma             Denmark      Caucasian        PB        QPCR[5](#nt105){ref-type="table-fn"}   359      765                          0.14                                          0.61
  Pereira         2010          Colorectal carcinoma             Portugal     Caucasian        HB                      PCR-RFLP                 117      256                          0.19                                          0.37
  Thompson        2009          Colorectal carcinoma             America      American         PB                      PCR-RFLP                 421      479                          0.16                                          0.29
  Ulrich          2005           Colorectal adenoma              America      American         PB                      PCR-RFLP                 494      584                          0.17                                          0.37
  Ueda            2008           Colorectal adenoma               Japan         Asian          PB                      PCR-RFLP                 455     1051                          0.03                                          0.32
  Gunter          2006           Colorectal adenoma              America      American         HB                      PCR-RFLP                 210      196                          0.15                                          0.46
  Kristinsson     2009               Esophageal                Netherlands    Caucasian        PB                      PCR-RFLP                 222      236                          0.18                                          0.47
  Upadhyay        2009               Esophageal                   India         Asian          HB                      PCR-RFLP                 174      216                          0.18                                          0.09
  Zhang           2005               Esophageal                   China         Asian          HB                      PCR-RFLP                 1026    1270                          0.02                                          0.43
  Moons           2007               Esophageal                Netherlands    Caucasian        PB                      PCR-RFLP                 140      495                          0.12                                          0.24
  Bye             2011               Esophageal                South Africa    African         PB                       Taqman                  347      462                          0.51                                          0.94
  Bye             2011               Esophageal                South Africa     mixed          PB                       Taqman                  190      422                          0.32                                          0.91
  Shin            2012                 Gastric                    Korea         Asian          HB                      PCR-RFLP                 100      100                          0.05                                          0.60
  Li              2012                 Gastric                    China         Asian          PB                      PCR-RFLP                 296      319                          0.07                                          0.62
  Hou             2007                 Gastric                    Poland      Caucasian        PB                       Taqman                  290      409                          0.16                                          0.90
  Liu             2006                 Gastric                    China         Asian          PB                     PCR-DHPLC                 247      427                          0.05                                          0.27
  Tang            2009                 Gastric                    China         Asian          PB                      PCR-RFLP                 100      105                          0.16                                          0.11
  Zhang           2011                 Gastric                    China         Asian          PB                      PCR-RFLP                 357      985                          0.02                                          0.46
  Sitarz          2008                 Gastric                 Netherlands    Caucasian        PB                    PCR-sequence               241      100                          0.25                                          0.14
  Pereira         2006                 Gastric                   Portugal     Caucasian        HB                      PCR-RFLP                  73      210                          0.22                                          0.28
  Saxena          2008                 Gastric                    India         Asian          HB                      PCR-RFLP                  62      241                          0.16                                          0.42
  Chang           2012   HCC[1](#nt101){ref-type="table-fn"}      China         Asian          HB                      PCR-RFLP                 298      298                          0.08                                          0.13
  He              2012                   HCC                      China         Asian          HB                      PCR-RFLP                 300      300                          0.07                                          0.59
  Peters          2009                   HNC                   Netherlands    Caucasian        HB                      PCR-RFLP                 428      433                          0.14                                          0.12
  Ben             2009   HNC[2](#nt102){ref-type="table-fn"}     Tunisia      Caucasian        HB                      PCR-RFLP                 180      169                          0.13                                          0.93
  Mittal          2010                   HNC                      India         Asian          HB                      PCR-RFLP                 176      96                           0.32                                          0.08
  Chiang          2008                   HNC                      China         Asian          HB                      PCR-RFLP                 178      205                          0.10                                          0.13
  Wang            2010                Leukimia                    China         Asian          HB                      PCR-RFLP                 266      266                          0.06                                          0.30
  Zheng           2011                Leukimia                    China         Asian          PB                      PCR-RFLP                 446      725                          0.02                                          0.56
  Coskunpinar     2011                  lung                      Turkey      Caucasian        HB                      PCR-RFLP                 231      118                          0.50                                          0.20
  liu             2010                  lung                      China         Asian          HB                        QPCR                   358      716                          0.07                                          0.06
  Campa           2004                  lung                      Norway      Caucasian        PB                      PCR-RFLP                 250      214                          0.10                                          0.19
  Monroy          2011                Lymphoma                   America      American         HB                      PCR-RFLP                 100      100                          0.87                                          0.48
  Hoeft           2008                Lymphoma                   Germany      Caucasian        PB                      PCR-RFLP                 668      661                          0.15                                          0.18
  Chang           2009                Lymphoma                   America      American         PB                      PCR-RFLP                 454      354                          0.19                                          0.39
  Agachan         2010                 Ovarian                    Turkey      Caucasian        HB                      PCR-RFLP                  57      111                          0.32                                          0.38
  Pinheiro        2010                 Ovarian                 Multicenter      mixed          PB                      PCR-RFLP                 1264    1756                          0.17                                          0.26
  Zhao            2009               Pancreatic                   China         Asian          PB                      PCR-RFLP                 393      786                          0.02                                          0.59
  Xu              2008               Pancreatic                   China         Asian          HB                      PCR-RFLP                 283      566                          0.02                                          0.61
  Cheng           2007                Prostate                   America       African         HB                      PCR-RFLP                  89      88                           0.35                                          0.61
  Cheng           2007                Prostate                   America      Caucasian        HB                      PCR-RFLP                 416      417                          0.16                                          0.98
  Murad           2009                Prostate                      UK        Caucasian        PB                      PCR-RFLP                 1592    3028                          0.16                                          0.06
  Catsburg        2012                Prostate                   America      American         PB                      PCR-RFLP                 1431     756                          0.21                                          0.21
  Wu              2011                Prostate                    China         Asian          HB                      PCR-RFLP                 218      436                          0.08                                          0.06
  Joshi           2012                Prostate                   America      American         PB                      PCR-RFLP                 935      756                          0.21                                          0.21
  Panguluri       2004                Prostate                   Nigeria       African         PB                   Pyrosequencing              146      108                          0.14                                          0.12
  Balistreri      2010                Prostate                    Italy       Caucasian        HB                      PCR-RFLP                  50      125                          0.30                                          0.19
  Vogel           2007                  Skin                     Denmark      Caucasian        PB                        QPCR                   304      315                          0.12                                          0.93
  Lira            2007                  Skin                      Italy       Caucasian        PB                      PCR-RFLP                 105      129                          0.18                                          0.59
  Cocos           2012                  Skin                     Romania      Caucasian        HB                      PCR-RFLP                 174      80                           0.22                                          0.44
  Pandey          2010                Cervical                    India         Asian          HB                      PCR-RFLP                 200      200                          0.10                                          0.09
  Schwartzbaum    2005              Glioblastoma                  Sweden      Caucasian        PB                      PCR-DASH                 108      399                          0.15                                          0.65
  Biramijamal     2011         Colorectal& Esophageal              Iran       Caucasian        PB                      PCR-RFLP                  60      103                          0.18                                          0.26

HCC: hepatocellular carcinoma;

HNC: head and neck cancer.

MAF: minor allele frequency;

HWE: Hardy-Weinberg equilibrium.

QPCR: quantitative PCR.

Quantitive Analysis {#s3b}
-------------------

The main results of the meta-analysis are listed in [**Table 2**](#pone-0073213-t002){ref-type="table"}. The association between COX-2-765 G\>C polymorphism and cancer risk was estimated in two comparison models: a co-dominant model (GC vs. GG) and a dominant model ((CC+GC) vs. GG). The analysis used a random pooling model because the heterogeneity among studies was significant in the co-dominant model and in the dominant model (p\<0.001). In the co-dominant model, the overall pooled effect indicated that the-765 GC heterozygote was associated with a significantly increased overall cancer risk, compared with the GG homozygote (OR = 1.11, 95% CI = 1.02--1.22, P = 0.01). In stratification analyses by cancer type and ethnicity, the association was maintained in gastric cancer (OR = 1.53, 95% CI = 1.04--2.24, p = 0.03), leukemia (OR = 1.86, 95% CI = 1.32--2.62, P\<0.01), pancreatic cancer (OR = 2.51, 95% CI = 1.73--3.66, P\<0.01), and cancer in the Asian population (OR = 1.41, 95% CI = 1.16--1.72, p\<0.01) ([**Fig. 2A and B**](#pone-0073213-g002){ref-type="fig"}). Notably, the association between the COX-2-765 C allele and decreased cancer risk was found in the Caucasian population (OR = 0.91, 95% CI = 0.83--1.00, P = 0.04). However, this difference may have been the result of different ethnic subjects and bias from different genotyping methods. In the dominant model, we found significant associations of this SNP with cancer risk in overall cancer susceptibility (OR = 1.12, 95% CI = 1.02--1.23, P = 0.01), gastric cancer (OR = 1.60, 95% CI = 1.02--2.50, P = 0.04), leukemia (OR = 1.91, 95% CI = 1.36--2.69, P\<0.01), pancreatic cancer (OR = 2.51, 95% CI = 1.73--3.66, P\<0.01), and cancer in the Asian population (OR = 1.42, 95% CI = 1.15--1.76, P\<0.01) ([**Fig. 2C and D**](#pone-0073213-g002){ref-type="fig"}).

![Forest plot of cancer risk associated with the COX-2-765 G\>C polymorphism stratified by cancer type and ethnicity.\
GC vs. GG in the co-dominant model by the random effects for (A) gastric cancer, leukemia, pancreatic cancer and (B) in the Asian population. (CC+GC) vs. GG in a dominant model by the random-effects for (C) gastric cancer, leukemia, pancreatic cancer and (D) in the Asian population.](pone.0073213.g002){#pone-0073213-g002}
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###### Quantitive synthesis of the associations between COX-2-765 G\>C polymorphism and cancer risk in two models.

![](pone.0073213.t002){#pone-0073213-t002-2}

                                            No of studies   GC vs. GG OR (95%CI)      P       P~heterogeneity~   CC+GC vs. GG OR (95%CI)      P       P~heterogeneity~
  ---------------------------------------- --------------- ---------------------- ---------- ------------------ ------------------------- ---------- ------------------
  **Total**                                      67         **1.11(1.02--1.22)**   **0.01**       **0.00**        **1.12(1.02--1.23)**     **0.01**       **0.00**
  **Cancer type**                                                                                                                                    
  Gastric                                         9         **1.53(1.04--2.24)**   **0.03**       **0.00**        **1.60(1.02--2.50)**     **0.04**       **0.00**
  Leukemia                                        2         **1.86(1.32--2.62)**   **0.00**       **0.41**        **1.91(1.36--2.69)**     **0.00**       **0.33**
  Pancreatic                                      2         **2.51(1.73--3.66)**   **0.00**       **0.95**        **2.51(1.73--3.66)**     **0.00**       **0.95**
  Colorectal carcinoma                           13           1.03(0.88--1.21)       0.58           0.02            1.04(0.90--1.20)         0.60           0.06
  Prostate                                        8           0.92(0.77--1.10)       0.36           0.01            0.90(0.75--1.70)         0.22           0.01
  Esophageal                                      6           1.28(0.89--1.84)       0.19           0.00            1.31(0.92--1.87)         0.14           0.00
  HNC                                             4           1.11(0.80--1.54)       0.52           0.09            1.10(0.76--1.60)         0.60           0.03
  Breast                                          4          0.95(0.80--1.132)       0.58           0.12            0.97(0.82--1.14)         0.70           0.12
  Colorectal adenoma                              3           0.88(0.63--1.23)       0.45           0.13            0.87(0.64--1.20)         0.84           0.16
  Skin                                            3           1.01(0.74--1.22)       0.94           0.30            1.06(0.81--1.39)         0.69           0.36
  Lung                                            3           0.86(0.66--1.12)       0.27           0.43            0.80(0.57--1.13)         0.20           0.57
  Lymphoma                                        3           0.98(0.75--1.27)       0.86           0.23            0.99(0.71--1.40)         0.96           0.11
  HCC                                             2           1.24(0.43--3.58)       0.70           0.00            1.29(0.41--4.07)         0.66           0.00
  Ovarian                                         2           1.62(0.48--5.51)       0.44           0.00            1.47(0.52--4.17)         0.47           0.00
  Other[\*](#nt106){ref-type="table-fn"}          3           1.30(0.61--2.76)       0.49           0.01            1.33(0.53--3.32)         0.55           0.00
  **Ethnicity**                                                                                                                                      
  Asian                                          25         **1.41(1.16--1.72)**   **0.00**       **0.00**        **1.42(1.15--1.76)**     **0.00**       **0.00**
  Caucasian                                      25           1.04(0.92--1.17)       0.53           0.00            1.04(0.92--1.18)         0.51           0.00
  African                                         3           0.67(0.35--1.27)       0.22           0.02            0.64(0.35--1.18)         0.15           0.02
  American                                        9           1.03(0.93--1.13)       0.58           0.65            1.02(0.93--1.12)         0.69           0.55
  Mixed                                           5         **0.91(0.83--1.00)**   **0.04**       **0.84**          0.93(0.85--1.02)         0.10           0.51

Cancers studied in only one article were combined and termed "other."

Heterogeneity, Sensitivity Analysis, and Publication Bias {#s3c}
---------------------------------------------------------

Heterogeneity was determined using the χ^2^-based Q-test, and heterogeneity was found in two pooling models (P\<0.01 in both models), so the random model was utilized to generate a larger pool of studies with 95% CIs. We performed the sensitivity analysis by assessing the influence of an individual study on the overall OR. No individual study affected the pooled OR markedly, since omission of any single study made no substantial difference. Also, we conducted Begger's funnel plot and Egger's test to assess the publication bias of all eligible literature. The shapes of the funnel plot seemed symmetrical in two comparison models, and statistical results from Egger's test still did not show publication bias (p = 0.36 in co-dominant model and p = 0.34 in dominant model). These findings demonstrated that publication bias, if any, did not significantly affect the results of our meta-analysis for the association between COX-2-765G\>C and cancer risk.

Discussion {#s4}
==========

COX-2-765G\>C is a functional polymorphism, located at 765 bp upstream (-765 bp) from the transcription start site. It changes a putative stimulatory protein (Sp1) binding site in the promoter of COX-2 between-766 and-761 bp [@pone.0073213-Papafili1], but it creates an E2 promoter factor (E2F) binding site, leading to high transcription activity, which may be the mechanism of COX-2-765G\>C polymorphism increasing cancer risk [@pone.0073213-Szczeklik1].

The current meta-analysis explored the role of COX-2-765G\>C polymorphism in the susceptibility of cancer among 65 articles with 29487 cancer cases and 39212 non-cancer controls. We found that C-allele carriers had an increased risk of cancer, especially gastric cancer, leukemia, and pancreatic cancer and cancer in the Asia population, when compared with G carriers. Our results show that COX-2-765 C carriers are at significantly increased risk for gastric cancer, leukemia, and pancreatic cancer but not other cancer types. One possible explanation is that different types of cancer have various mechanism of carcinogenesis. Additionally, it is possible that the significant difference effects are casual, because studies with small sample sizes have deficient statistical power to disclose a slight effect. Interestingly, our meta-analysis revealed an association between the COX-2-765 C allele and decreased cancer risk in Caucasian population. In this Caucasian subgroup, a large study sample with 6254 cases and 8092 controls (two thirds of all subjects in this subgroup) showed an MAF (0.84) [@pone.0073213-Dossus1] significantly higher than in other reports, which may have affected the results. Additionally, this extremely high MAF value may have resulted from bias induced by experimental procedure and methods. Our study differed from previous meta-analyses in the subgroup analysis of gastric and colorectal cancer. Zhu reported a significant association between-765G\>C polymorphisms and colorectal carcinoma, but not in gastric cancer, contrary to the results of our present study [@pone.0073213-Zhu1]. In other studies, researchers analyzed the role of COX-2-765G\>C polymorphism in diverse cancer types. No convincing association between the C allele and risk of prostate cancer [@pone.0073213-Dong1], [@pone.0073213-Zhang3], breast cancer [@pone.0073213-Yu1], and colorectal cancer [@pone.0073213-Cao2] respectively, were revealed, but a significant association was reported between C allele and risks for gastric cancer [@pone.0073213-Pereira3] and esophageal cancer [@pone.0073213-Liang1]. However, the number of subjects included in previous studies was not as large, and our meta-analysis includes the latest studies. Furthermore, we analyzed at least twice as many studies as meta-analyses published previously [@pone.0073213-Zhu1]. In summary, our findings provide the most current and powerful conclusion among analyses of this type.

Limitations encountered in this analysis should be considered as these results are interpreted. First, the CC genotype frequency in many studies was zero, so we assumed a co-dominant model and a dominant model. For some polymorphisms, this model might not be the most suitable for a clear assessment of the gene--disease interaction. Secondly, the results of the subgroup stratification analysis must be interpreted with caution because of the limited number of published studies. For example, only two reports for leukemia and pancreatic cancer were included. Thirdly, there is marked heterogeneity among studies in overall and some subgroup analyses, which may derive from ethnic groups and types of cancer, may have skewed our results. Finally, this systematic review was based on unadjusted data, as the genotype information stratified for the main confounding variables was not available in the original papers and the confounding factors addressed across the different studies varied. Adjusted estimates might provide more precise and stronger associations, as they reduced the impact of possible confounding factors. To determine a precise association between the COX-2-765G\>C and cancer genetic susceptibility, it is essential to design and perform scientific and rigorous studies with large sample sizes in the future.

Although further research is needed, this present meta-analysis validates a significant association between COX-2-765G\>C polymorphism and genetic cancer susceptibility, especially in gastric cancer, leukemia, pancreatic cancer, and cancer in the Asian population. If confirmed in future studies, this genotype may be used by clinicians to select individuals for early diagnosis and treatments.
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